Long acting buprenorphine treatment for opioid addiction in France
A Prospective Observational Study in Naturalistic Settings to Describe Long Acting Buprenorphine Introduction in France: Change in Severity of Addiction and Health Related Quality of Life Over a Period of 6 Months.
This study is testing if long-acting buprenorphine can help people in France with opioid addiction stick to their treatment better and manage their cravings.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 223 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University of Bordeaux Academic / other |
| Locations | 1 site (Bordeaux, Gironde) |
| Trial ID | NCT06266039 on ClinicalTrials.gov |
What this trial studies
This observational study aims to evaluate the effectiveness of long acting buprenorphine (LAB) formulations, such as Buvidal, for treating opioid use disorder (OUD) in France. It addresses the challenges associated with daily buprenorphine or methadone treatments, including compliance and misuse risks. By utilizing Patient Reported Outcome Measures (PROMs) and Ecological Momentary Assessment (EMA), the study will gather real-life data on patient experiences and treatment adherence over a six-month period. The goal is to better understand the dynamics of craving and treatment retention in a naturalistic setting.
Who should consider this trial
Good fit: Ideal candidates are adults over 18 who have been prescribed long acting buprenorphine and plan to initiate treatment soon.
Not a fit: Patients who are under guardianship or have difficulty understanding the French language may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could improve treatment adherence and outcomes for patients with opioid use disorder.
How similar studies have performed: Previous studies have shown promising results for long acting buprenorphine, but this specific approach in the French healthcare context is novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * To have been prescribed LAB * To plan to initiate a LAB treatment in the following month * To be over 18 years of age * To accept to participate after an informed consent procedure Exclusion Criteria: * To be under guardianship, curatorship or safeguard of justice * To have a difficulty understand / reading the French language * To have any condition incompatible with study participation (e.g., not being able to communicate by phone)
Where this trial is running
Bordeaux, Gironde
- University of Bordeaux — Bordeaux, Gironde, France (Recruiting)
Study contacts
- Study coordinator: Marc Auriacombe, Professor
- Email: marc.auriacombe@u-bordeaux.fr
- Phone: +33556561738
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.